What this pack is
RAPAFLO is the brand name in this record; silodosin capsules is the generic name. Read both together with the dosage form (oral capsule).
PACK CHECK · MARKET FIRST
RAPAFLOGeneric namesilodosin capsules
How this medicine works
The historical label explains that silodosin blocks post-synaptic alpha-1 receptors in the prostate, bladder base/neck, prostatic capsule and prostatic urethra, relaxing smooth muscle in these tissues to improve urine flow and reduce BPH-related symptoms. In-vitro work showed high affinity for the alpha-1A subtype. Mechanism cannot diagnose the cause, exclude prostate cancer or determine individual treatment.
Read source: United States ↗Historical public record · reviewed 2026-09-02More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- RAPAFLO
- Source-scoped market brand names
- RAPAFLO · United States (historical)Historical public record ↗NDA 022206; the historical 4 mg and 8 mg RLD rows are currently DISCN and do not establish current brand supply.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
- Generic name
- silodosin capsules
- Dosage-form class
- Silodosin 4 mg/8 mg oral hard-gelatin capsules (historical originator-brand RAPAFLO). RAPAFLO, FLOMAX, UROXATRAL, CARDURA/CARDURA XL, HYTRIN, MINIPRESS and dutasteride-containing combinations are separate exact products. A shared purpose or alpha-blocking mechanism creates no milligram conversion, capsule-opening, combination, alternation or substitution rule.
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
3 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Historical U.S. originator-brand DailyMed label (revised Dec 2020; marketing for this NDC ended 2026-03-31)
8 mg silodosin per capsule; 30-capsule child-resistant bottle; historical RLD, currently DISCN
- Product code
- NDC 0023-6142-30
- Form and route
- RAPAFLO silodosin oral hard-gelatin capsule (historical originator brand) · oral (historical brand product-identity field)
- Container
- child-resistant bottle
- Listing review
- Cited product evidence reviewed 2026-09-02; actual marketing, stock and availability are not established.
- silodosin
- 8 mghistorical brand amount per capsule; not an individual's capsule count, frequency or conversion to another alpha blocker
- Package
- 30 capsules per bottle
- Labelled appearance
- white opaque · hard-gelatin capsule; approximately 19 mm · imprint WATSON 152 / 8 mgCapsule; score status does not apply and this does not imply permission to open it
United States label · Historical U.S. originator-brand DailyMed label (revised Dec 2020; marketing for this NDC ended 2022-12-31)
8 mg silodosin per capsule; 90-capsule child-resistant bottle; historical RLD, currently DISCN
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 0023-6142-90
- Form and route
- RAPAFLO silodosin oral hard-gelatin capsule (historical originator brand) · oral (historical brand product-identity field)
- Container
- child-resistant bottle
- Listing review
- Cited product evidence reviewed 2026-09-02; actual marketing, stock and availability are not established.
- silodosin
- 8 mghistorical brand amount per capsule; not an individual's capsule count, frequency or conversion to another alpha blocker
- Package
- 90 capsules per bottle
- Labelled appearance
- white opaque · hard-gelatin capsule; approximately 19 mm · imprint WATSON 152 / 8 mgCapsule; score status does not apply and this does not imply permission to open it
United States label · Historical U.S. originator-brand DailyMed label (revised Dec 2020; marketing for this NDC ended 2026-03-31)
4 mg silodosin per capsule; 30-capsule child-resistant bottle; historical RLD, currently DISCN
- Product code
- NDC 0023-6147-30
- Form and route
- RAPAFLO silodosin oral hard-gelatin capsule (historical originator brand) · oral (historical brand product-identity field)
- Container
- child-resistant bottle
- Listing review
- Cited product evidence reviewed 2026-09-02; actual marketing, stock and availability are not established.
- silodosin
- 4 mghistorical brand amount per capsule; not an individual's capsule count, frequency or conversion to another alpha blocker
- Package
- 30 capsules per bottle
- Labelled appearance
- white opaque · hard-gelatin capsule; approximately 16 mm · imprint WATSON 151 / 4 mgCapsule; score status does not apply and this does not imply permission to open it
PUBLIC LABEL IMAGE
Appearance and package-text clues
This dated or historical public-label image is for checking the brand, generic-name, strength and dosage-form clues only. It does not authenticate a product or establish originator status, a current label, current packaging, target-market approval or sale eligibility.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
RAPAFLO enlarged label: separate 4/8 mg per capsule, bottle count and historical-brand status
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
Four or eight milligrams is the silodosin amount per capsule; 30/90 Capsules is the historical-brand bottle count. FDA currently lists both brand strengths as DISCN. The label remains useful for safety reading but does not establish current brand stock or calculate an individual's capsule count.
- The label warns that postural hypotension, dizziness or syncope can occur when starting treatment. Older adults, people with low blood pressure or falls, and those using antihypertensives should prioritise review of blood pressure, the complete medicine list and exact packs with a clinician or pharmacist; do not self-separate or stop a pack.
- Kidney function affects exposure. The historical label contraindicates severe renal impairment and specifies a different strength pathway for moderate impairment. The site does not select 4 mg, 8 mg, capsule count or timing from a laboratory value; the responsible team must assess the current product and prescription.
- Strong CYP3A4 inhibitors (including ketoconazole, itraconazole, clarithromycin and ritonavir in the label) are contraindicated, and strong P-gp inhibitors such as ciclosporin are not recommended. Moderate CYP3A4 inhibitors such as verapamil or erythromycin also require careful review. Do not self-space, halve or temporarily stop medicines.
- The label says not to combine with other alpha blockers and notes that PDE-5 inhibitors and antihypertensives may increase orthostatic effects. Similar use or mechanism does not permit self-conversion, combination, alternation or substitution by milligrams.
- Before cataract or another eye procedure, tell the eye team about current or previous RAPAFLO/other alpha-1 blocker use, even after stopping. The label does not support self-stopping for surgery.
- For fainting, a fall with injury, a persistent painful erection or another acute severe problem, prioritise local emergency medical services; do not wait for a webpage decision or self-counteract with another medicine.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-09-02
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 3
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): historical U.S. originator-brand RAPAFLO silodosin 4/8 mg label, patient safety information and two exact package panels (revised Dec 2020; brand NDC marketing ended) ↗Historical public record · reviewed 2026-09-02
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- U.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-09-02DailyMed (NLM): historical U.S. RAPAFLO electronic label PDF (enlargeable; not evidence of current brand supply) ↗Historical public record · reviewed 2026-09-02
- FDA · United States · Regulatory product record or label archive · 2026-08-29FDA Orange Book current data entry: both historical RAPAFLO/silodosin RLD strengths under NDA 022206 are listed as DISCN ↗reviewed 2026-08-29
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about RAPAFLO (silodosin capsules). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
RAPAFLO is the brand in this record and silodosin capsules is the active-ingredient name. Check both with the dosage form (Silodosin 4 mg/8 mg oral hard-gelatin capsules (historical originator-brand RAPAFLO). RAPAFLO, FLOMAX, UROXATRAL, CARDURA/CARDURA XL, HYTRIN, MINIPRESS and dutasteride-containing combinations are separate exact products. A shared purpose or alpha-blocking mechanism creates no milligram conversion, capsule-opening, combination, alternation or substitution rule.) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): historical U.S. originator-brand RAPAFLO silodosin 4/8 mg label, patient safety information and two exact package panels (revised Dec 2020; brand NDC marketing ended) ↗Historical public record · reviewed 2026-09-02
- DailyMed (NLM): historical U.S. RAPAFLO electronic label PDF (enlargeable; not evidence of current brand supply) ↗Historical public record · reviewed 2026-09-02
- FDA Orange Book current data entry: both historical RAPAFLO/silodosin RLD strengths under NDA 022206 are listed as DISCN ↗reviewed 2026-08-29
HOW IT WORKS · NOT A TREATMENT PLAN
How silodosin works: selective blockade of post-synaptic alpha-1 adrenoceptors in the lower urinary tract
- RAPAFLO and RAPAMUNE have similar names but are entirely different medicines: RAPAFLO is silodosin and RAPAMUNE is sirolimus. A photo or text showing only a RAP prefix requires the full brand, generic, strength and package code; it must not auto-match.
- RAPAFLO, FLOMAX, UROXATRAL, CARDURA/CARDURA XL, HYTRIN and MINIPRESS are not one medicine. A related alpha-blocking mechanism creates no milligram conversion, alternation, combination or substitution rule.
- “Improves urine flow” does not support self-diagnosis of benign prostatic hyperplasia. Difficulty urinating, retention, blood in urine, fever, pain or changing symptoms require timely professional assessment; do not start or switch from age or another person's experience.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): historical U.S. originator-brand RAPAFLO silodosin 4/8 mg label, patient safety information and two exact package panels (revised Dec 2020; brand NDC marketing ended) ↗Historical public record · reviewed 2026-09-02
- DailyMed (NLM): historical U.S. RAPAFLO electronic label PDF (enlargeable; not evidence of current brand supply) ↗Historical public record · reviewed 2026-09-02
- FDA: original approval letter for RAPAFLO (silodosin) capsules under NDA 022206 (4 mg/8 mg; 8 Oct 2008) ↗reviewed 2026-09-02
- FDA Orange Book current data entry: both historical RAPAFLO/silodosin RLD strengths under NDA 022206 are listed as DISCN ↗reviewed 2026-08-29
SOURCE-TRACEABLE ARCHIVE
RAPAFLOsilodosin capsules
This page links to public primary-source material for RAPAFLO. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
FDA approved RAPAFLO
The original approval letter confirms 4 mg and 8 mg silodosin capsules and the BPH-related labelled use.
FDA: original approval letter for RAPAFLO (silodosin) capsules under NDA 022206 (4 mg/8 mg; 8 Oct 2008) ↗Marketing record ended for the historical 8 mg, 90-capsule pack
NDC 0023-6142-90 is used only as a historical product identity after this date.
DailyMed (NLM): historical U.S. originator-brand RAPAFLO silodosin 4/8 mg label, patient safety information and two exact package panels (revised Dec 2020; brand NDC marketing ended) ↗Marketing records ended for the last two listed originator-brand NDCs
Package panels for NDC 0023-6142-30 and 0023-6147-30 are historical references after this date; both strengths are currently DISCN in the Orange Book.
FDA Orange Book current data entry: both historical RAPAFLO/silodosin RLD strengths under NDA 022206 are listed as DISCN ↗
MARKET SCOPE
Market-record boundary
United States
Historical RLD; both 4 mg and 8 mg currently DISCNOriginator-brand package panels and the electronic label are retained as historical material and do not establish current brand stock.
Mainland China and other markets
Current regulatory records require market-by-market reviewNames such as 优利福 require item-by-item checking against the local regulator, current leaflet and pack in hand; U.S. historical-brand status does not establish local approval or supply.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
RECORD FAQ
Record questions
Do 4 mg and 8 mg tell me how many capsules to take each day?
No. They are historical-brand amounts of silodosin per capsule; 30/90 is the bottle count. The responsible team must assess the current exact product, prescription, kidney function and full medicine list to determine strength, capsule count, timing and suitability; the site does not calculate them.
Can the capsule be opened, half emptied or mixed with food?
Do not infer this from the capsule shape. The historical label contains a specific swallowing-difficulty route, but it cannot be transferred across manufacturers or markets or used outside the prescription, and it never permits visually emptying half for dose reduction. Ask a pharmacist to check the current label for the exact product in hand.
Can it be switched to FLOMAX, UROXATRAL or CARDURA?
That conclusion cannot be drawn from a similar use or related alpha-blocking mechanism. Their ingredients, dosage forms, strengths, NDAs and labels differ; do not self-convert, combine or alternate them milligram for milligram.
Can the package panel identify an originator-brand pack available now?
No. The two panels come from a historical DailyMed originator-brand label, the related NDC marketing records have ended, and FDA currently lists both RAPAFLO strengths as DISCN. A current pack requires separate review of all text, manufacturer, NDC or approval information and the target market's official record.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.